Abbott agrees to withdraw obesity drug Meridia from U voluntarily.S avanafil 100mg . Market Abbott Laboratories agrees to withdraw its obesity drug MeridiaAbbott Laboratories has decided to voluntarily withdraw its obesity medication Meridia from the U.S. Market because of clinical trial data indicating an increased risk of heart attack and stroke, the U.S. Meals and Medication Administration announced today. ‘Meridia’s continued availability isn’t justified when you compare the modest weight loss that people achieve upon this medication to their threat of heart attack or stroke,’ said John Jenkins, M.D., director of any office of New Medications in the FDA’s Center for Medication Evaluation and Research .
In the Biotherapeutic segment, Biotest researches in to the clinical development of monoclonal antibodies, including in the indications of rheumatoid malignancy and arthritis of plasma cells. Biotest has more than 1.600 employees worldwide. The choice shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. About Abbott Abbott is a global, broad-based health care company specialized in the discovery, development, marketing and manufacture of pharmaceuticals and medical items, including nutritionals, devices and diagnostics. The company employs 90 nearly, 000 markets and people its products in more than 130 countries.. Abbott and Biotest Announce Global Agreement to build up and Commercialize Novel Antibody for Autoimmune Diseases Abbott and Biotest AG announced a worldwide agreement to build up and commercialize BT-061, a novel anti-CD4 antibody for the treatment of arthritis rheumatoid and psoriasis.